WisBusiness: Archeus Technologies, WARF launching clinical trial this year for cancer targeting molecule - Wisconsin Technology Council

WisBusiness: Archeus Technologies, WARF launching clinical trial this year for cancer targeting molecule - Wisconsin Technology Council

Archeus Technologies in Madison and WARF are launching a clinical trial this year for a targeting molecule used in treating prostate cancer. The organizations yesterday announced the plans to further develop ART-101, a receptor-based targeting molecule developed at UW-Madison’s Advanced Radiotheranostics lab. It’s designed to deliver radioactive isotopes within the body as part of a

Archeus Technologies partners with WARF to advance ART-101

This partnership will advance the receptor-based targeting molecule into clinical development. Under the agreement terms, Archeus Technologies will be responsible for leading the Phase I clinical development of The post Archeus Technologies partners with WARF to advance ART-101 for prostate cancer appeared first on Pharmaceutical Business review.